Home Drug IndexClinical Monograph

Sucralfate Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

Therapeutic Class

Gastrointestinal agent

Subclass

Mucosal protectant (Cytoprotective agent)

Speciality

Gastroenterology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets: 500 mg, 1 g
Oral suspension: 500 mg/5 mL, 1 g/10 mL
Oral gel: 1 g/5 mL (limited availability)

Note: Topical use for mucositis is off-label and limited to specialist oncology/radiation therapy settings.

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Peptic Ulcer Disease (Gastric and Duodenal Ulcer)

Parameter	Recommendation
Starting dose	1 g orally, four times daily (1 hour before meals and at bedtime)
Titration	Not applicable
Usual maintenance dose	1 g twice daily (after ulcer healing, for maintenance)
Maximum dose	4 g/day

Clinical Notes:

Administer on empty stomach for optimal mucosal binding
Treatment duration: 4–8 weeks for active ulcer healing
Maintenance therapy: 1 g BD for up to 12 months to prevent recurrence
Avoid antacids within 30 minutes before or after sucralfate dose
Continue H. pylori eradication if indicated concurrently

2. Gastro-oesophageal Reflux Disease (GORD) — Adjunctive Therapy

Parameter	Recommendation
Starting dose	1 g orally, four times daily (before meals and at bedtime)
Titration	Not applicable
Usual maintenance dose	1 g four times daily
Maximum dose	4 g/day

Clinical Notes:

Used as adjunct to PPI or H2RA for mucosal protection
Particularly useful in erosive oesophagitis
Duration: 4–8 weeks depending on clinical response
Not first-line monotherapy for GORD

3. Stress Ulcer Prophylaxis in High-Risk Hospitalised Patients

Parameter	Recommendation
Starting dose	1 g orally or via nasogastric tube, every 6 hours
Titration	Not applicable
Usual maintenance dose	1 g every 6 hours
Maximum dose	4 g/day

Clinical Notes:

Used in ICU/critical care settings
Alternative when PPI/H2RA contraindicated or not preferred
May have lower risk of nosocomial pneumonia compared to acid-suppressive agents
Specialist/intensivist discretion required
Flush nasogastric tube before and after administration

Secondary Indications — Adults Only (Off-label)

Indication	Dose	Duration	Notes
Radiation-induced mucositis (oral)— OFF-LABEL	1 g/10 mL suspension: swish in mouth for 1–2 minutes, then spit or swallow; 4 times daily	During radiation therapy and 2 weeks post-completion	Specialist only (Radiation Oncology). Based on institutional protocols and supportive RCTs. Provides mucosal coating and symptomatic relief.
Chemotherapy-induced mucositis — OFF-LABEL	1 g/10 mL suspension: swish and swallow or spit; 4 times daily	During chemotherapy cycles	Specialist only (Medical Oncology). Limited evidence; used in Indian tertiary cancer centres.
Bile reflux gastritis — OFF-LABEL	1 g orally QID before meals	4–8 weeks	Specialist gastroenterology supervision. May bind bile acids and protect mucosa.

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

1. Peptic Ulcer Disease (Gastric/Duodenal Ulcer)

Weight-based Dosing:

Weight/Age	Dose	Frequency	Maximum Daily Dose
Children >1 year	40–80 mg/kg/day	Divided into 4 doses (before meals and bedtime)	4 g/day
Adolescents (>12 years)	1 g per dose	4 times daily	4 g/day

Dosing Structure:

Parameter	Recommendation
Starting dose	40 mg/kg/day orally, divided into 4 doses
Titration	May increase to 80 mg/kg/day if inadequate response
Usual maintenance dose	40–80 mg/kg/day in 4 divided doses
Maximum dose	80 mg/kg/day or 4 g/day, whichever is lower

Administration:

Give 1 hour before meals and at bedtime
Use oral suspension for accurate dosing in younger children

Secondary Indications — Paediatric (Off-label)

Indication	Age	Dose	Duration	Notes
GORD with erosive oesophagitis — OFF-LABEL	>1 year	40–80 mg/kg/day in 4 divided doses	4–8 weeks	Paediatric gastroenterologist only. Use in combination with acid suppression (PPI). Short-term use for severe erosive disease. Based on IAP recommendations and specialist practice.
NSAID-induced gastropathy prophylaxis — OFF-LABEL	>6 years	40 mg/kg/day in 4 doses	Duration of NSAID therapy	Specialist supervision. Limited paediatric data.

Age Restrictions:

Not recommended below 1 year of age due to insufficient safety and efficacy data
Neonates and infants: Avoid use except under specialist paediatric gastroenterology supervision

Safety Monitoring in Children:

Monitor for constipation (most common adverse effect)
Assess growth parameters if prolonged use planned
Check renal function if therapy exceeds 8 weeks
Ensure adequate hydration

Renal Adjustments

eGFR (mL/min/1.73m²)	Recommendation
>50	No dose adjustment required
30–50	Use with caution; avoid prolonged therapy (>4 weeks). Monitor for aluminium accumulation.
10–30	Avoid unless benefit clearly outweighs risk. If used, limit to short course (<2 weeks). Monitor aluminium levels if available.
<10	Avoid use. High risk of aluminium accumulation and toxicity.
Haemodialysis	Avoid. Aluminium is poorly dialysable and accumulates.
Peritoneal dialysis	Avoid. Same accumulation risk.

Note: Sucralfate contains aluminium hydroxide. Chronic use in renal impairment can lead to aluminium toxicity (encephalopathy, osteomalacia, microcytic anaemia). If use is unavoidable, monitor serum aluminium levels.

Hepatic adjustment

Contraindications

Known hypersensitivity to sucralfate or any component of the formulation
Known or suspected gastrointestinal obstruction
Dysphagia with high aspiration risk (for oral suspension — relative contraindication)

Cautions

Chronic kidney disease (eGFR <30 mL/min) — aluminium accumulation risk
Concurrent use with aluminium-containing antacids — additive aluminium load
Diabetes mellitus — oral suspension contains sucrose; monitor blood glucose
Patients with impaired swallowing or reduced consciousness — aspiration risk with suspension
Patients on multiple oral medications — drug absorption interference
Gastroparesis or delayed gastric emptying — bezoar formation risk
Chronic use (>8 weeks) — monitor for phosphate depletion

Pregnancy

Parameter	Information
Overall safety	Generally considered safe; minimal systemic absorption (<5%)
Risk assessment	No evidence of teratogenicity in animal or limited human studies
Preferred alternatives	PPIs (omeprazole, pantoprazole) are first-line for peptic ulcer in pregnancy; sucralfate is acceptable alternative
When to use	May be used when acid suppression agents are not preferred or as adjunct therapy
Monitoring	Maternal nutritional status; avoid prolonged use due to theoretical phosphate depletion

Lactation

Parameter	Information
Compatibility	Compatible with breastfeeding
Milk levels	Negligible (minimal systemic absorption)
Preferred alternatives	None required; sucralfate is acceptable during lactation
Infant monitoring	Routine observation for feeding and bowel patterns

Elderly

Parameter	Recommendation
Starting dose	1 g four times daily (same as adults)
Titration	Not applicable
Special considerations	Higher risk of constipation; ensure adequate hydration and fibre intake
Renal function	Assess baseline renal function before initiating; avoid prolonged use if eGFR <30
Polypharmacy	Multiple drug interactions due to binding; ensure appropriate spacing of medications
Monitoring	Bowel function; signs of aluminium toxicity if prolonged use in those with reduced renal reserve

Major drug interactions

Drug/Class	Interaction	Mechanism	Management
Fluoroquinolones(ciprofloxacin, levofloxacin, ofloxacin, norfloxacin)	Significantly reduced fluoroquinolone absorption and efficacy	Chelation with aluminium in sucralfate	Administer fluoroquinolone 2 hours before or 6 hours aftersucralfate
Tetracyclines (doxycycline, tetracycline)	Markedly reduced tetracycline absorption	Chelation	Give tetracycline 2 hours before sucralfate
Levothyroxine	Reduced thyroid hormone absorption	Binding in GI tract	Administer levothyroxine 4 hours before sucralfate; monitor TSH
Phenytoin	Reduced phenytoin absorption; risk of seizure breakthrough	GI binding	Give phenytoin 2 hours beforesucralfate; monitor phenytoin levels
Digoxin	Reduced digoxin bioavailability	GI binding	Administer digoxin 2 hours before sucralfate
Ketoconazole, Itraconazole	Reduced antifungal absorption (require acidic environment)	Reduced gastric acidity from aluminium; binding	Avoid combination if possible; if needed, give antifungal 2 hours before

Moderate drug interactions

Drug/Class	Interaction	Management
Aluminium-containing antacids	Additive aluminium load; increased toxicity risk	Avoid concurrent use, especially in renal impairment
Warfarin	Possible reduced warfarin absorption	Monitor INR when initiating or stopping sucralfate; give warfarin 2 hours before
Iron supplements	Reduced iron absorption	Give iron supplements 2 hours before sucralfate
PPIs and H2RAs	May reduce sucralfate efficacy (requires acidic environment for optimal binding)	Clinically used together; give sucralfate separately from PPI
Theophylline	Possible reduced theophylline absorption	Monitor theophylline levels; give 2 hours apart
Ranitidine/Famotidine	Reduced H2RA absorption if given together	Separate administration by 2 hours
Antiepileptics(carbamazepine, valproate)	Potential reduced absorption	Separate by 2 hours; monitor clinical response

Common Adverse effects

Constipation (most frequent, up to 10%)
Dry mouth
Nausea
Abdominal discomfort, bloating
Flatulence
Indigestion
Metallic taste
Headache

Serious Adverse effects

Effect	Notes
Aluminium toxicity	Occurs with prolonged use in chronic renal failure; presents as encephalopathy (confusion, memory impairment, myoclonus), osteomalacia (bone pain, fractures), microcytic anaemia. Discontinue and refer if suspected.
Bezoar formation	Rare; occurs in patients with gastroparesis or gastric outlet obstruction. May require endoscopic or surgical removal.
Hypophosphataemia	With chronic use; aluminium binds dietary phosphate. Monitor phosphate in long-term therapy.
Anaphylaxis/Angioedema	Extremely rare. Discontinue immediately if suspected.

Monitoring requirements

Timing	Parameters
Baseline	Renal function (serum creatinine, eGFR) — especially in elderly and those with known CKD; assess concurrent medications for interaction potential
After initiation/dose change	Monitor bowel function (constipation); ensure drug spacing is maintained
Long-term use (>8 weeks)	Serum phosphate levels; signs of aluminium toxicity (if renal impairment); nutritional status
In renal impairment	Serum aluminium levels (if available and prolonged use); phosphate; haemoglobin (for aluminium-related anaemia)

Brands in India

Single Ingredient:

Sucral (Dr. Reddy's)
Sucrafil (Cipla)
Ulcerfate (Sun Pharma)
Sucralfate (Generic — multiple manufacturers)
Hapifate (Micro Labs)
Sucrabest (Mankind)
Ulgel (Torrent)
Sucralcoat (Alkem)

Fixed Dose Combinations (FDCs):

Sucralfate + Oxetacaine (Sucral-O, Mucaine Gel — NOT sucralfate alone)

Note: Mucaine-S contains aluminium hydroxide + magnesium hydroxide + oxetacaine — NOT sucralfate. Do not confuse with sucralfate products.

Price range (INR)

Formulation	Price Range
Tablet 500 mg	₹2–5 per tablet
Tablet 1 g	₹3–8 per tablet
Suspension 1 g/10 mL (100 mL bottle)	₹50–90 per bottle
Suspension 500 mg/5 mL (100 mL bottle)	₹40–70 per bottle
Gel 1 g/5 mL (100 mL)	₹60–100 per bottle

Note: Not included in NLEM 2022. Prices not NPPA-controlled; vary by brand. Available under Jan Aushadhi scheme as generic sucralfate at lower cost.

Clinical pearls

Empty stomach administration: Sucralfate works by binding to ulcerated mucosa — give 1 hour before meals and at bedtime for optimal effect. Food in stomach impairs binding.
Drug spacing is critical: Due to extensive binding of co-administered drugs, maintain 2-hour gap (or more for specific drugs like levothyroxine — 4 hours). This is the most common prescribing error with sucralfate.
Renal caution: Avoid prolonged use (>4 weeks) in patients with eGFR <30 mL/min due to aluminium accumulation risk. Short courses may be acceptable with monitoring.
Constipation management: Most common side effect. Advise adequate fluid intake and dietary fibre. Consider stool softeners if persistent.
Stress ulcer prophylaxis advantage: Unlike PPIs and H2RAs, sucralfate does not significantly raise gastric pH, potentially reducing nosocomial pneumonia risk in ICU patients — may be preferred in selected cases.
Not a substitute for H. pylori eradication: In peptic ulcer disease, always test for and treat H. pylori infection. Sucralfate provides symptomatic relief and mucosal protection but does not address underlying infection.

Version

RxIndia v1.0 — 05 Jan 2025

Reference

CDSCO approved prescribing information
Indian Pharmacopoeia / National Formulary of India
NLEM 2022 (not listed)
API Textbook of Medicine
AIIMS Drug Formulary
PGI Chandigarh hospital protocols
IAP Paediatric Drug Formulary
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Select RCTs for off-label mucositis indications

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.